Oncopeptides AB (publ) (STO:ONCO)

Market Cap	324.07M
Revenue (ttm)	27.07M
Net Income (ttm)	-282.39M
Shares Out	215.19M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,473
Average Volume	1,117,889
Open	1.416
Previous Close	1.514
Day's Range	1.464 - 1.536
52-Week Range	1.280 - 8.300
Beta	-0.30
RSI	50.16
Earnings Date	Feb 21, 2025

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 57
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2023, Oncopeptides AB's revenue was 35.22 million, an increase of 321.54% compared to the previous year's 8.36 million. Losses were -249.11 million, -26.29% less than in 2022.